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A new tool, ‘naked DNA’, has
recently become available to those
involved in vaccine development. It
shows great promise for both the
improvement of existing vaccines and
the development of vaccines against
disease targets for which there are so
far no effective vaccines. And yet the
discovery that naked DNA could be
used in vaccination came about more
or less by accident, as a result of
attempts to use non-replicating
bacterial plasmid expression vectors
(encoding proteins of interest) for
gene therapy.
In experiments designed to test
the use of cationic liposomes (lipid-
based packages) for delivering
plasmid DNA into cells, it was found
that the ‘control’ animals, into which
naked DNA alone was injected
intramuscularly, expressed the highest
levels of the transgenic protein. This
unexpected discovery suggested a
new approach to immune stimulation.
If animals could be transfected by
injection with DNA, such that the
encoded protein was expressed in situ,
would immunity specific to this
protein (the antigen) result?
The answer is yes. In 1993, studies
in mice showed that intramuscular
injection of plasmid DNA encoding
influenza virus antigens generated
immune responses from both the
humoral system (antibodies and B
cells) and the cell-mediated system
(cytotoxic T cells); these immune
responses were sufficient to protect
the animals against a live influenza
virus infection (see Figure 1). These
results set off a flurry of research and
development activity leading to the
more than 700 papers on DNA
vaccines in the literature today.
Advantages of DNA vaccines
There are numerous practical and
scientific reasons for developing
DNA vaccine technology, beginning
with the fact that there are many
potential disease targets for which
there are no effective vaccines.
Established vaccine technology has
failed to produce effective vaccines
against significant infections such as
tuberculosis, chlamydia, papilloma
virus and malaria. Furthermore, there
are currently no effective anti-tumor
vaccines. Vaccines directed against
cancers may require technology that
can stimulate a vigorous
T-cell-mediated immune response
against tumors expressing the
antigen, but conventional vaccine
technology using recombinant or
purified subunit antigens (see blue
box) often fails to stimulate cell-
mediated responses.
Given that some infectious
pathogens and cancers are dealt with
most effectively by T-cell-mediated
immune responses, DNA vaccine
technology was conceived as a means
of stimulating antigen-specific cell-
mediated immunity. The scientific
rationale was that the expressed
antigen could be processed (digested
into peptide fragments) in the cell
and peptides from it displayed on
cell-surface molecules of the major
histocompatibility complex (MHC
class I). This sort of ‘antigen
presentation’ is necessary for the
stimulation of T-cell-mediated
immunity. Indeed, consistent with
the original concept, DNA
vaccination can be shown to
stimulate antigen-specific
cell-mediated immunity.
But other immunological evidence
suggested that this immune response
would not have been triggered simply
by antigen-expressing muscle cells,
because they do not carry all of the
cell-surface molecules needed to
stimulate cytotoxic T cells. Other,
professional antigen-presenting cells
must have been involved. Several labs
subsequently provided evidence that
the T-cell-mediated responses to
DNA vaccines are mediated through
bone-marrow-derived cells, but the
details of how the antigen reaches
these cells following DNA vaccination
have not been definitively
established. Even though the
mechanistic details are not completely
understood, one of the hallmarks of
DNA vaccination is the reliable
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Figure 1
Results of an experiment in which mice were
vaccinated with either plasmid DNA
encoding influenza virus antigen (red) or
‘control’ blank plasmid (blue). The mice were
then challenged with influenza virus. All the
control mice died and all those vaccinated
with influenza antigen survived.
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Induced immunity to infectious agents can
be achieved in several ways. One is to
deliberately cause a mild infection using a
live 'attenuated' form of the organism with
reduced pathogenicity. This stimulates a
long-lasting humoral and cell-mediated
immunity but carries a risk: live attenuated
bacterial and viral preparations can
sometimes revert to active infectious forms.
Vaccines of this type include the original
smallpox virus vaccine pioneered by Jenner
in 1796, Pasteur's chicken cholera bacteria
vaccine, and current vaccines for measles,
mumps and rubella.
A safer method is to use killed microbial or
recombinant subunit preparations, which
can not lead to infection. But these are not
so potent, need the addition of adjuvants
(substances that are mixed with an antigen
to boost the immune response) and tend
primarily to stimulate humoral immunity.
Vaccines in this class include the original
polio vaccine, influenza, tetanus toxoid, and
hepatitis A and B vaccines.
By contrast, naked DNA vaccines are not
infectious and stimulate long-lasting
humoral and cell-mediated immunity
without the need for adjuvants. 
Types of vaccine
development of a robust, antigen-
specific cytotoxic T-cell response.
Another characteristic of DNA
vaccination is its ability to induce an
antigen-specific antibody (humoral)
immune response. Humoral
immunity, like cellular immunity, is
mediated by helper T cells, which
can be grouped into functional
subsets, Th1 and Th2. Whereas
vaccination with DNA leads to a
Th1-dominated response,
vaccination with recombinant
proteins or killed viruses leads to a
Th2-dominated response. Immune
responses to allergy-causing proteins
(allergens) are also Th2-dominated,
and result in the production of IgE
antibodies. DNA vaccination using
plasmids encoding allergens can shift
a pre-existing immune response to
an allergen from the Th2 to the Th1
type, leading to an inhibition of IgE
antibody production. This raises the
possibility that DNA vaccination
could be used to attenuate allergic
responses to allergens.
DNA vaccination can also be
used to generate antibody-producing
cells for the production of
hybridomas that produce monoclonal
antibodies. Using DNA eliminates
the need to isolate and purify the
protein antigen for inoculation.
Because the specific type of
MHC molecules expressed by a
person (their HLA haplotype)
determines which peptides
(epitopes) within the antigen protein
will be presented on the cell surface,
conventional peptide-based vaccines
must contain many different peptides
to cover all of the haplotypes that are
present in the normal outbred human
population. But with DNA vaccines,
one can use large, full-length protein
antigens, allowing the immune
system to select the appropriate
epitopes according to the individual’s
own HLA haplotype. In addition,
unlike the situation for many
vaccines based on recombinant
proteins, the antigen is produced in
its native form. In situations where it
would be advantageous to direct
immune responses to specific
epitopes of a protein, DNA vaccines
could be developed which express
many different peptide epitopes as
‘minigenes’.
DNA vaccines are also more stable
and easier to manipulate than purified
proteins. Different proteins require
different purification procedures but
all plasmids, regardless of the
sequences they encode, can be
purified using the same procedures.
Plasmid DNA is very stable, offering
the potential for the development of a
vaccine that can be stored at ambient
temperatures. This may have practical
implications for the delivery of stable
vaccines to developing countries.
From test tube to cell
Experimentally, DNA vaccines are
simple to manipulate. Plasmid is
suspended in a simple saline solution
and 10–500 µg is injected into the
quadriceps muscle. This results in
the uptake of the DNA by, and
antigen expression in, muscle cells
(Figure 2). Another common method
of administering DNA vaccines is by
particle bombardment, in which cells
of the dermis and epidermis are
transfected as a result of direct
penetration by DNA-coated gold
beads. Using this method,
antigen-presenting cells, such as
Langerhans cells found in the skin,
may be directly transfected, so
inducing the cell-mediated and
humoral immune responses.
Different antigens can be readily
examined by simply cloning
different genes into expression
plasmids and injecting them into
experimental animals. Multiple
plasmids encoding different antigens
can be administered at the same
time. Antigen-specific immune
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(a) The gene for a microbial antigen is
cloned in a plasmid. (b) The cloned gene is
injected into muscle tissue. (c) The plasmid
is expressed in muscle cells and the antigen
it encodes is presented on the muscle cell
surface by MHC class I molecules. Some
intact antigen also escapes out of the
muscle cell into the extracellular space. The
details of how antigen stimulates the immune
response are not completely understood. It
is not known how antigen escapes the
muscle cells and eventually stimulates
antigen-presenting cells, or whether there is
any role for processed antigen on the muscle
cells in stimulating the immune response. 
responses begin within one or two
weeks after injection. Although there
is some antigen-dependent variation,
the immune responses are stable,
often lasting for the lifetime of the
animal. Boosting with a second
plasmid injection or with
recombinant protein has been shown
to augment the immune response.
Intramuscular expression from
plasmids peaks at about 14 days, and
then sharply declines. Antigen-
specific cytotoxic T cells mediate the
decline in expression by killing the
muscle cells expressing the foreign
antigen, or by eliminating the muscle
cell nuclei responsible for antigen
expression. The immune system
does not, however, completely
eliminate the entire population of
antigen-expressing cells and a low
level of antigen expression continues
for many months or even years after
the onset of the immune response.
The longevity of the immune
response observed with DNA
vaccination may be related to this
persistent antigen expression, which
would keep the immune response
continuously primed. 
Future developments
Many different microorganisms and
cancer-associated antigens have been
targeted with DNA vaccines (see
green box). There are human clinical
trials under way of DNA vaccines
directed against influenza, HIV-1,
malaria, hepatitis B, carcinoembryonic
antigen and the MHC molecule
HLA-B7 (as an immunostimulant, to
direct immune responses against
many different forms of cancer). More
human clinical trials can be expected.
Scientifically, there are many
basic questions that are not yet
resolved. Although bone-marrow-
derived antigen-presenting cells
seem to be involved in the response
to DNA vaccines, it is not clear how
the antigen gets into these cells after
an intramuscular plasmid injection.
There are also differences among
animal species with regard to their
susceptability to DNA
immunization. Mice, dogs, chickens,
cows and fish seem to be rather easy
to immunize, whereas chimpanzees
and cats are more difficult. The
reasons for these differences are not
understood and a better
understanding should lead to more
effective DNA vaccines. There is not
necessarily a correlation between the
level of gene product expressed at
the site of injection and the strength
of the resulting immune response.
Research is under way to
determine whether the co-expression
of immunostimulatory lymphokines,
co-stimulatory molecules or adjuvants
could help to boost the immune
response to DNA. Another simple
way of enhancing immune responses
to DNA vaccines is via an adjuvant
effect of the DNA itself. Evidence is
emerging that certain CpG-rich
sequences in the plasmid can have an
adjuvant effect. Such motifs within
the DNA seem to boost the efficacy
of the DNA vaccine by inducing
cytokine secretion and lymphocyte
activation, but the details of these
effects need to be evaluated further.
So, with all of these interesting
and practical features, will DNA
vaccines eventually replace all other
types of vaccine? The progress of
pharmaceutical development usually
moves steadily towards simpler, more
chemically defined materials; it is
therefore likely that chemically
simpler products, such as DNA
vaccines and peptide- or
recombinant-protein-based vaccines,
will replace killed and live-attenuated
virus vaccines. And whereas
recombinant-protein-based vaccines
usually require ‘boosting’ at regular
intervals to keep the immune
response primed, the antibody
response to a single dose of DNA
vaccine remains primed for a long
time, presumably because the antigen
is persistently expressed. DNA
vaccines are particularly effective at
producing long-lived cell-mediated
immunity, which is beneficial for
vaccines against many viral, parasitic
and bacterial pathogens, as well as for
anti-cancer vaccines for which an
antibody response alone is not
sufficiently protective. 
The discovery and development
of DNA vaccines has had many
surprising twists during the past ten
years, and all the signs point to a very
bright future over the next ten years.
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Viruses
Avian influenza, bovine herpes, bovine
viral diarrhea virus, dengue fever,
encephalitis, feline immunodeficiency
virus, hepatitis B, hepatitis C, human
cytomegalovirus, herpes simplex virus,
human immunodeficiency virus I,
influenza, lymphocytic choriomeningitis
virus, measles, papilloma, rabies,
respiratory syncitial virus, simian
immunodeficiency virus, simian virus 40.
Bacteria
Borrelia burgdorferi (Lyme disease),
Moraxella bovis, Mycobacterium
tuberculosis, Mycoplasma, Ricketsia,
Salmonella, tetanus toxin.
Parasites
Cryptosporidium parvum, Leishmania,
Plasmodium falciparum (malaria),
Schistosoma.
Cancer-associated antigens
Carcinoembryonic antigen (CDA),
melanoma-associated antigen, the MHC
molecule HLA-B7.
Disease targets for
which DNA vaccines
have been tested in
animals
